B

Beaumont Hospital | Cancer Clinical Trials and Research Unit

Research site
(Unclaimed)
Location
CCTU, Beaumont Hospital, Dublin 9, Dublin, Leinster, Ireland
Site insights

Top conditions

Breast Cancer (29 trials)

Fibrosis (11 trials)

Cystic Fibrosis (10 trials)

Sclerosis (9 trials)

Non-Small-Cell Lung Carcinoma (8 trials)

Top treatments

Trastuzumab
Docetaxel
Filgotinib
Anastrozole
Letrozole
Carboplatin
Paclitaxel
Bevacizumab
Epirubicin
Dexamethasone

Parent organization

This site is a part of Beaumont Hospital

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Trials

27 of 180
Status: Active
Trial type: Interventional
Funder type: Industry

Filters
3
A Phase 3 Study to Assess Efficacy and Safety of Tafasitamab Plus Lenalidomide and Rituximab Compared to Placebo Plus Lenalidomide and Rituximab in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma or Marginal Zone Lymphoma. (InMIND)

This is a Phase 3 double-blind, placebo-controlled, randomized study designed to investigate whether tafasitamab and lenalidomide as an add-on to rit...

Active, not recruiting
Marginal Zone Lymphoma
Follicular Lymphoma
Drug: rituximab
Drug: placebo

This is a Phase 3,multicenter, randomized, open-label, blinded endpoint evaluation study comparing the effect of abelacimab relative to apixaban on v...

Enrolling
Pulmonary Embolism
Venous Thromboembolism
Biological: Abelacimab
Drug: Apixaban

This is a Phase 3, multicenter, open-label, blinded endpoint study to evaluate the effect of abelacimab relative to dalteparin on venous thromboembol...

Enrolling
Pulmonary Embolism
Venous Thromboembolism
Biological: Abelacimab
Drug: Dalteparin

This is a Phase III, global, randomized, open-label, multicenter, study evaluating the efficacy and safety of adjuvant giredestrant compared with end...

Enrolling
Early Breast Cancer
Drug: Endocrine Therapy of Physician's Choice
Drug: Abemaciclib

This is a multiple dose, randomized, placebo-controlled, double-blind study of belcesiran to evaluate the safety, tolerability, PK, and PD in adult p...

Active, not recruiting
Alpha 1-Antitrypsin Deficiency
Drug: Belcesiran
Other: Placebo

The purpose of this study is to evaluate the efficacy and safety of guselkumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Guselkumab
Drug: Placebo
Locations recently updated

This study is being done to find out if tucatinib with other cancer drugs works better than standard of care to treat participants with HER2 positive...

Enrolling
Colorectal Neoplasms
Drug: oxaliplatin
Drug: cetuximab

The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS)...

Active, not recruiting
Acute Myeloid Leukemia (AML)
Drug: Placebo
Drug: Venetoclax

This study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out...

Enrolling
Kidney Disease, Chronic
Drug: Placebo
Drug: BI 764198

ADEPPT is an international, multicentre, single-arm phase II trial. The protocol treatment consists of adagrasib, which is administered at a dose of...

Enrolling
NSCLC Stage IV
KRAS P.G12C
Drug: Adagrasib

The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in participants with moderately to severely active ulcerative colitis...

Active, not recruiting
Ulcerative Colitis
Drug: Mirikizumab
Drug: Placebo

This study is a Phase Ib, open label, single arm, adaptive multi-centre clinical study. The target population for this study are patients with relaps...

Active, not recruiting
Multiple Myeloma
Drug: Dexamethasone
Drug: Pomalidomide

The current study population will consist of adult patients with congenital alpha-1 antitrypsin (AAT) deficiency who have moderate or severe airflow...

Enrolling
Alpha 1-Antitrypsin Deficiency
Drug: Alpha 1-Antitrypsin
Drug: Placebo

The primary objective of this study is to observe the long-term safety of filgotinib in adults who have completed or met protocol specified efficacy...

Active, not recruiting
Ulcerative Colitis
Drug: Filgotinib
Drug: Placebo

The FAST III is a randomized controlled, open-label, multicenter, international, non-inferiority, strategy trial. A total of 2228 participants will b...

Enrolling
Coronary Artery Disease
Device: vFFR guided revascularization
Device: FFR guided revascularization

This is an international, multicentre, double-blind, controlled, randomized phase II study comparing the efficacy and safety of fulvestrant in combin...

Active, not recruiting
Breast Neoplasms
Drug: Fulvestrant
Drug: Placebo

This study aims to evaluate the stringent Complete Response (sCR) rate by the end of two cycles of induction treatment, defined as the proportion of...

Enrolling
Multiple Myeloma
Drug: Lenalidomide
Drug: Isatuximab

The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compar...

Active, not recruiting
Renal Cell Carcinoma
Drug: Lenvatinib
Drug: Sunitinib

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of es...

Active, not recruiting
Breast Cancer
Drug: Letrozole
Other: Placebo

PICCOLO (IMGN853-0419) is a Phase 2 multicenter, open label study designed to evaluate the safety and efficacy of Mirvetuximab Soravtansine in partic...

Active, not recruiting
Peritoneal Cancer
Fallopian Tube Cancer
Drug: Mirvetuximab soravtansine

Trial sponsors

C

Cancer Trials Ireland (32 trials)

AbbVie logo

AbbVie (7 trials)

Clinical trials

Find clinical trialsTrials by location

Resources

© Copyright 2024 Veeva Systems